11/5
07:00 am
lrmr
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
Medium
Report
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
10/30
06:00 pm
lrmr
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
Medium
Report
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
10/29
12:10 pm
lrmr
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
10/28
10:00 am
lrmr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
10/23
10:00 am
lrmr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
10/22
12:16 pm
lrmr
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
Low
Report
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
10/18
10:00 am
lrmr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
10/16
04:44 am
lrmr
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR
Medium
Report
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR
10/16
04:40 am
lrmr
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Medium
Report
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
10/15
09:30 pm
lrmr
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR
Low
Report
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR
10/15
09:09 pm
lrmr
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
10/13
01:50 pm
lrmr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
10/8
04:36 pm
lrmr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
10/4
09:40 am
lrmr
Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? [Yahoo! Finance]
Low
Report
Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? [Yahoo! Finance]
10/2
09:37 am
lrmr
Larimar Therapeutics (NASDAQ:LRMR) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $26.00 to $21.00. They now have an "outperform" rating on the stock.
Medium
Report
Larimar Therapeutics (NASDAQ:LRMR) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $26.00 to $21.00. They now have an "outperform" rating on the stock.
9/30
08:48 am
lrmr
Larimar Therapeutics (NASDAQ:LRMR) had its price target lowered by analysts at Wedbush from $15.00 to $11.00. They now have an "outperform" rating on the stock.
Medium
Report
Larimar Therapeutics (NASDAQ:LRMR) had its price target lowered by analysts at Wedbush from $15.00 to $11.00. They now have an "outperform" rating on the stock.
9/30
08:01 am
lrmr
Larimar Therapeutics (NASDAQ:LRMR) was given a new $7.00 price target on by analysts at Robert W. Baird.
Medium
Report
Larimar Therapeutics (NASDAQ:LRMR) was given a new $7.00 price target on by analysts at Robert W. Baird.